Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcutaneous Neostigmine and Glycopyrrolate for Bowel Evacuation in SCI
NCT02370862Phase 1Completed
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Feb 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neostigmine and glycopyrronium in neurogenic bowel (NBD) and spinal cord injury (SCI), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoint: Biological Responses to Study Drugs at 6 months. Started Feb 2013; status: completed.
02
Drugs
neostigmineglycopyrronium
03
Conditions
neurogenic bowel (NBD)spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02370862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370862.